Bicara (BCAX) Director Jeremy Bender Receives Equity Award

What Happened Jeremy Bender, a director of Bicara Therapeutics, received an equity award on July 28, 2026: options covering 38,950 shares were granted at an exercise price of $0.00 (reported as acquired with $0 cash value in the Form 4). This is a compensation grant (derivative award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-28; filing date: 2026-07-29 (filed the next day).
• Instrument: Option award covering 38,950 shares (reported as derivative acquisition).
• Reported price: $0.00 (no cash paid at grant in the filing).
• Vesting (footnote): One-third vests on July 28, 2027; the remainder vests in 24 equal monthly installments thereafter, contingent on continued service.
• Shares owned after transaction: not specified in the supplied filing details.
• Filing timeliness: filed promptly the next day (no late filing flag noted).

Context This was a standard director compensation grant (options) rather than a market purchase or sale. Because the grant vests over time and there was no immediate exercise or sale, it does not represent an immediate change in market holdings or cash proceeds. Such awards are common for retaining directors and aligning incentives with shareholders.